Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Первый опыт использования тикагрелора в России
Первый опыт использования тикагрелора в России
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation of the European Society of Cardiology. Eur Heart J 2011; 32: 2999–3054.
2. Werkum JW et al. Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399–409.
3. Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434–41.
4. Lakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126–30.
5. Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondia-betic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007; 50: 501–8.
6. Aoki J, Lansky AJ, Mehran R et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterizationand Urgent Intervention Triage Strategy trial. Circulation 2009; 119: 687–98.
7. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large twoinstitutional cohort study. Lancet 2007; 369: 667–78.
8. Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin Pract Endocrinol Metab 2007; 3: 46–56.
9. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181–8.
10. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045–57.
11. Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double–blind study. Lancet 2010; 375 (9711): 283–93.
12. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery, results from the PLATO. J Amer Coll Cardiol 2011; 57: 672–84.
2. Werkum JW et al. Predictors of Coronary Stent Thrombosis: The Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53: 1399–409.
3. Urban P, Gershlick AH, Guagliumi G et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434–41.
4. Lakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126–30.
5. Machecourt J, Danchin N, Lablanche JM et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondia-betic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007; 50: 501–8.
6. Aoki J, Lansky AJ, Mehran R et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterizationand Urgent Intervention Triage Strategy trial. Circulation 2009; 119: 687–98.
7. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large twoinstitutional cohort study. Lancet 2007; 369: 667–78.
8. Rask-Madsen C, King GL. Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat. Clin Pract Endocrinol Metab 2007; 3: 46–56.
9. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26: 2181–8.
10. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045–57.
11. Cannon CP, Harrington RA, James S et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double–blind study. Lancet 2010; 375 (9711): 283–93.
12. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery, results from the PLATO. J Amer Coll Cardiol 2011; 57: 672–84.
Авторы
1,2О.Л.Барбараш, 1,2В.В.Кашталап
1. ФГБУ НИИ комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения Российской академии медицинских наук;
2. ГБОУ ВПО Кемеровская государственная медицинская академия Минздрава РФ
1. ФГБУ НИИ комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения Российской академии медицинских наук;
2. ГБОУ ВПО Кемеровская государственная медицинская академия Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.